A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin

References

• SzakácsGPatersonJKLudwigJABooth-GentheCGottesmanMMTargeting multidrug resistance in cancerNat Rev Drug Discov2006521923416518375
   PubMed Web of Science ®Google Scholar
• GottesmanMMFojoTBatesSEMultidrug resistance in cancer: role of ATP dependent transportersNat Rev Cancer20022485811902585
   PubMed Web of Science ®Google Scholar
• LooTWClarkeDMRecent progress in understanding the mechanism of P-glycoprotein-mediated drug effluxJ Membr Biol2005206173185
   PubMed Web of Science ®Google Scholar
• FoxEBatesSETariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitorExpert Rev Anticancer Ther2007744745917428165
   PubMed Web of Science ®Google Scholar
• KlopmanGShiLMRamuAQuantitative structure activity relationship of multidrug resistance reversal agentsMol Pharmacol1997523233349271356
   PubMed Web of Science ®Google Scholar
• SikicBIFisherGALumBLHalseyJBeketic-OreskovicLChenGModulation and prevention of multidrug resistance by inhibitors of P-glycoproteinCancer Chemother Pharmacol199740S13199272128
   PubMed Web of Science ®Google Scholar
• KolitzJEGeorgeSLMarcucciGP-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Blood20101161413142120522709
   PubMed Web of Science ®Google Scholar
• AbrahamJEdgerlyMWilsonRA phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbineClin Cancer Res2009153574358219417029
   PubMed Web of Science ®Google Scholar
• RuffPVorobiofDAJordaanJPA randomized, placebo-controlled, double-blind Phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimenCancer Chemother Pharmacol20096476376819241078
   PubMed Web of Science ®Google Scholar
• DaiCLXiongHYTangLFTetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in miceCancer Chemother Pharmacol20076074175017273824
   PubMed Web of Science ®Google Scholar
• WangGLemosJRTetrandrine: a new ligand to block voltage-dependent Ca-2+ and Ca-2+-activated K+ channelsLife Sci1995562953067837929
   PubMed Web of Science ®Google Scholar
• FuLLiangYDengLCharacterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistanceCancer Chemother Pharmacol20045334935614666379
   PubMed Web of Science ®Google Scholar
• JinJWangFPWeiHLiuGTReversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrineCancer Chemother Pharmacol20055517918815378274
   PubMed Web of Science ®Google Scholar
• HuYLFuYHTabataYGaoJQMesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapyJ Control Release201014715416220493219
   PubMed Web of Science ®Google Scholar
• KimKYNanotechnology platforms and physiological challenges for cancer therapeuticsNanomedicine2007310311017442621
   PubMed Web of Science ®Google Scholar
• SahooSKLabhasetwarVNanotech approaches to drug delivery and imagingDrug Discov Today200381112112014678737
   PubMed Web of Science ®Google Scholar
• MahmoudiMSimchiAImaniMMilaniASStroevePOptimal design and characterization of superparamagnetic iron oxide nanoparticles coated with polyvinyl alcohol for targeted delivery and imagingJ Phys Chem B2008112144701448118729404
   PubMed Web of Science ®Google Scholar
• EndicottJALingVThe biochemistry of P-glycoprotein-mediated multidrug resistanceAnnu Rev Biochem1989581371712570548
   PubMed Web of Science ®Google Scholar
• LothsteinLIsraelMSweatmanTWAnthracycline drug targeting: cytoplasmic versus nuclear – a fork in the roadDrug Resist Updat2001416917711768330
   PubMed Web of Science ®Google Scholar
• GuoJZhouJYingXEffects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cellsJ Pharm Pharmaceut Sci201013136151
   PubMed Web of Science ®Google Scholar
• WangJChenBAChengJSynthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles in vitroInt J Nanomedicine2010620321121445276
   PubMed Web of Science ®Google Scholar
• XuJPJiJChenWDShenJCNovel biomimetic polymersomes as polymer therapeutics for drug deliveryJ Control Release200510750251216154659
   PubMed Web of Science ®Google Scholar
• ChengJWuWWChenBAEffect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cellsInt J Nanomedicine2009420921619918367
   PubMed Web of Science ®Google Scholar
• LingVMultidrug resistance: molecular mechanisms and clinical relevanceCancer Chemother Pharmacol199740S389272126
   PubMed Web of Science ®Google Scholar
• HorwitzSBCohenDRaoSRingelIShenHJYangCPTaxol: mechanisms of action and resistanceJ Natl Cancer Inst Monogr19931555617912530
   PubMedGoogle Scholar
• ChenBAChengJWuYNReversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-miceInt J Nanomedicine20094737819421372
   PubMed Web of Science ®Google Scholar
• ChenBAWangJDingJHReversal of P-glycoprotein-dependent resistance to adriamycin by 5-bromotetrandrine in K562/A02 cell line [abstract]J Clin Oncol200826Suppl13557
   Web of Science ®Google Scholar
• IyerAKKhaledGFangJMaedaHExploiting the enhanced permeability and retention effect for tumor targetingDrug Discov Today20061181281816935749
   PubMed Web of Science ®Google Scholar
• MiettinenSGrenmanSYlikomiTInhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposureAnticancer Drugs20092026727619262372
   PubMed Web of Science ®Google Scholar
• SusaMIyerAKRyuKDoxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcomaBMC Cancer2009939919917123
   PubMed Web of Science ®Google Scholar
• JainTKMoralesMASahooSKIron oxide nanoparticles for sustained delivery of anticancer agentsMol Pharm2005219420515934780
   PubMed Web of Science ®Google Scholar